

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)						
Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001						
Audited Standalone Financial Results for the Quarter and Year Ended 31st March 2021						
PART I (Rs. In Lakhs) except EPS						
Sl.No	Particulars	3 months ended (31-03-2021)	3 months ended (31-12-2020)	Corresponding 3 months ended (31-03-2020)	Current Year Ended (31.03.2021)	Previous Year Ended (31.03.2020)
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue From operations	2,184.05	1,747.53	1,313.28	7,121.79	4,247.24
II	Other Income	30.76	3.91	(67.06)	74.93	25.53
III	Total Income (I+II)	2,214.81	1,751.44	1,246.23	7,196.72	4,272.78
IV	EXPENSES					
a)	Cost of materials consumed	1,015.75	1,114.74	640.74	4,250.95	3,024.25
b)	Purchases of Stock-in-Trade	-	-	-	-	1.90
c)	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	248.64	3.71	(172.28)	294.60	(323.78)
d)	Employee benefits expense	392.17	325.37	308.26	1,198.41	1,025.16
e)	Finance costs	37.54	32.89	2.52	74.19	9.55
f)	Depreciation and amortization expenses	149.88	101.85	52.49	447.82	326.66
g)	Other expenses	107.24	82.83	111.60	348.07	396.84
	Total expenses (IV)	1,951.21	1,661.40	943.33	6,614.05	4,460.58
V	Profit/(loss) before exceptional items and tax (I-IV)	263.60	90.04	302.90	582.67	(187.80)
VI	Exceptional Items			(160.79)	-	(2,332.56)
VII	Profit/ (loss) before exceptions items and tax(V-VI)	263.60	90.04	142.11	582.67	(2,520.36)
VIII	Tax expense:					
	(1) Current tax					
	(2) Deferred tax			157.78		
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	263.60	90.04	(15.67)	582.67	(2,520.36)
X	Profit/(loss) from discontinued operations					
XI	Tax expenses of discontinued operations					
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)					
XIII	Profit/(loss) for the period (IX+XII)	263.60	90.04	(15.67)	582.67	(2,520.36)
	Other Comprehensive Income					
	A. (i) Items that will not be reclassified to profit or loss					
XIV	(ii) Income tax relating to items that will not be reclassified to profit or loss					
	B. (i) Items that will be reclassified to profit or loss or loss					
XV	Total Comprehensive Income for the period (XIII+XIV)Comprising Profit (Loss) and Other comprehensive Income for the period)	263.60	90.04	(15.67)	582.67	(2,520.36)
XVI	Earnings per equity share (for continuing operation):					
	(1) Basic	1.11	0.38	(0.66)	2.46	(106.54)
	(2) Diluted	1.11	0.38	(0.66)	2.46	(106.54)
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic					
	(2) Diluted					
XVIII	Earning per equity share (for discontinued & continuing operation)					
	(1)Basic	1.11	0.38	(0.66)	2.46	(106.54)
	(2) Diluted	1.11	0.38	(0.66)	2.46	(106.54)

1. The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee on 24.06.2021 and subsequently approved by the Board of Directors at their Meeting held on 25.06.2021

2. The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.

3. The above figures have been regrouped and Re- arranged Wherever considered necessary.

4. Being the Fourth Quarter of the year, Figures of the Quarter ended 31st March 2021 and Year to date for this Quarter are the balancing figures of the Year to date

5. Pursuant to the approval from the Directors of BAFNA PHARMACEUTICALS LIMITED in their Board Meeting held on 25.06.2020 and subsequent approval obtained from the share holders in the AGM held on 31.07.2020, the necessary application forms for striking off the Subsidiary Company namely M/s. BAFNA LIFESTYLES REMEDIES LIMITED were filed With MCA and The company M/s. BAFNA LIFESTYLES REMEDIES have been strike off. Hence, consolidation of financial statements not considered to be essential.

6. Due to migration from normal accounting package to SAP system, the Company has not valued inventories WIP on the basis of IND AS2 principle. as there was a sudden technical error in the absorption of overheads(related to Manufacture) in computation of BOM (Bill of Materials) consequently not enabling capturing of Overheads in Valuation of stocks of WIP(Work in Progress) and Finished Goods through SAP System. However Valuation of Closing Inventories have been computed Manually on Cost absorption Basis. The company is in the process of appointing an Costing Expert to bring the System in SAP.

7. The impact arising out of COVID-19 Pandemic on the future results of the Company will depend on developments, that are highly uncertain, including among other thing, any new information concerning the severity of the COVID-19 pandemic and any action to contain its spread or mitigate its impact whether government mandated or elected by the Company. The Company will continue to closely monitor any material changes in future economic conditions.

Place : Chennai
Date : 25.06.2021

For BAFNA PHARMACEUTICALS LIMITED
(Signature)
(S.HEMALATHA)
Whole Time Director
DIN :02714329



BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Standalone Balance Sheet as on

(Rs. In Lakhs)

Particulars	Stand Alone	
	As at 31st March 2021 Audited	As at 31 st March 2020 Audited
ASSETS		
Non-Current Assets		
(a) Property, Plant and Equipment	3,596.64	3,496.91
(b) Capital Work-in-Progress	83.13	21.21
(c) Goodwill		
(d) Other Intangible Assets		
(e) Financial Assets		
(i) Investments		
(ii) Trade Receivables		
(iii) Loans		
(iv) Other financials assets		
(g) Other Non-Current Assets		
Total Non-Current Assets	3,679.77	3,518.11
Current Assets		
(a) Inventories	1,544.34	1,141.15
(b) Financials Assets		
(i) Investments		
(ii) Trade Receivables	955.95	603.48
(iii) Cash and Cash Equivalents	180.37	848.02
(iv) Bank balance other than mentioned above		
(v) Loans		
(vi) Other financials assets	-	-
(c) Other Current Assets	2,286.16	995.34
(d) Assets classified as held for sale		
Total Current Assets	4,966.82	3,587.98
Total Assets (1+2)	8,646.59	7,106.10
EQUITY AND LIABILITIES		
(a) Equity Capital	2,365.63	236.56
(b) Other Equity	3,311.48	(677.60)
(c) Equity Share Warrants		5,535.58
Equity Attributable to Equity Shareholders	5,677.11	5,094.55
(d) Non controlling Interests	-	-
Total Equity	5,677.11	5,094.55
Liabilities		
(a) Non-Current Liabilities		
(i) Financial Liabilities		
- Borrowings	250.00	-
- Trade Payable		
- Other Financial Liabilities	278.60	301.76
(ii) Provisions		
(iii) Deferred Tax Liabilities (Net)		
(iv) Other non-current liabilities	10.00	-
Total Non-Current Liabilities	538.60	301.76
(b) Current Liabilities		
(i) Financial Liabilities		
- Borrowings		
- Trade Payable	1,069.16	1,254.14
- Dues to micro and small enterprises		
- Dues to Others		
- Other Financial Liabilities	1,000.00	
(ii) Other Current Liabilities	361.72	455.65
(iii) Provisions		
(iv) Current Tax Liabilities (net)		
Total Current Liabilities	2,430.87	1,709.79
Total Liabilities		
Total Equity and Liabilities	8,646.59	7,106.10

For BAFNA PHARMACEUTICALS LIMITED

Place : Chennai
Date : 25.06.2021

(S.HEMALATHA)
Whole Time Director
DIN : 02714329



BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Standalone Cash flow Statement

(Rs. In Lakhs)

Particulars	Stand Alone	
	As at 31st March 2021 Audited	As at 31st March 2020 Audited
Cash Flow from Operating Activities:		
Net Profit Before Tax and Including Exceptional Items	582.67	(2,520.36)
Adjustments for:		
Depreciation	447.82	326.66
Interest Paid	8.86	9.55
Interest Received	(3.95)	(3.94)
Other Income	(41.90)	(20.84)
Sundry Balance Write Back	(28.35)	
Lease Rent Received	(0.74)	(0.75)
Operating Profit before Working Capital Changes	964.41	(2,209.69)
Adjustment For:		
[Increase]/decrease in Inventories	(403.09)	(212.92)
[Increase]/decrease in Trade Receivables	(352.47)	1,879.90
[Increase]/decrease in Short Term Loans and Advances	(1,290.82)	147.11
Increase/[decrease] in Trade Payables	(184.98)	(2,688.26)
Increase/[decrease] in Other Current Liabilities	(93.94)	(342.93)
Cash generated from Operation	(1,360.89)	(3,426.80)
Less: Tax Paid	-	-
Net Cash Used in Operating Activity (A)	(1,360.89)	(3,426.80)
Cash Flow from Investing Activities:		
Sale of Fixed Assets	-	-
Purchase of Fixed Assets	(609.47)	(142.88)
Other Income	41.90	20.84
Interest Received	3.95	3.94
Lease Rent received	0.74	0.75
Deferred Tax Written Back	-	(617.87)
Sundry Balance Write Back	28.35	-
Changes in Long Term Loans and Advances	-	3,295.33
Change in Other Non- Current Assets	-	99.50
Net Cash used in Investing Activities (B)	(534.54)	2,659.62
Cash Flow from Financing Activities		
Issue of Shares, Warrants & Application Activities	-	5,535.58
Changes in Long Term Borrowings	250.00	(2,000.06)
Changes in Short Term Borrowings	986.84	(2,323.97)
Interest Paid	(8.86)	(9.55)
Increase / Decrease In investments	-	143.00
Net Cash from Financing Activities (C)	1227.98	1,345.01
Net Increase/ [Decrease] in Cash or Cash Equivalents [A+B+C]	(667.64)	577.82
Opening Balance of Cash & Cash Equivalents	180.37	270.19
Closing Balance of Cash & Cash Equivalents	848.02	848.02

Note :

Pursuant to Insertion of New Clause under Regulation 33, Sub-regulation (3), the company has prepared Standlone Cash Flows statement for the Year Ended 31st March 2021. The Statement of Cash Flows for the Year ended 31st March 2021, as reported in the statement have been approved by the Company's Board of Directors.

Place : Chennai
Date : 25.06.2021



For BAFNA PHARMACEUTICALS LIMITED

(S.HEMALATHA)

Whole Time Director
DIN : 02714329